BioGeneration Ventures


General information


Naarden, Noord-Holland


BioGeneration Ventures manages funds that are actively investing venture capital in the next generation of successful Biotech companies in Europe with a focus on The Netherlands, Belgium and Germany.

We focus on high potential companies active in therapeutics, medical devices, and diagnostics. The team of BioGeneration Ventures has a successful track record and a broad experience in the life sciences sector. Our involvement goes beyond only a financial investment. Having worked in startup and industry leaders ourselves our strategy is to generate value by working very closely with our portfolio companies and provide active hands-on support.

BioGeneration Ventures launched its first fund in 2006 and its second fund in 2012 both backed by a broad international and strategic investor base. We have achieved several exits and a very strong fund performance.  Following the exceptional exit results from our investments in Acerta Pharma and Dezima Pharma from our second fund in 2015, we have opened the fundraising for our third fund. On 1 July 2016, we have completed the first closing and we are now investing from this fund. 


Edward van Wezel (Managing Partner), Oskar Slotboom (Partner), Daniela Couto (Senior Associate), Joost Holthuis (Venture Partner), Rob de Ree (Operating Partner)

Investment information

Investment type

Early stage venture investments

Investment size

250K – 2,5M

Investing in

Biotechnology, life Sciences

Investments made

Acerta Pharma, Arcarios, arGEN-X, BioCeros, Cristal Therapeutics, Dezima Pharma, EPD-vision, FlexGen, Lathio Pharma, Medisse, Mucosis, NovioGendix, Progentic Orthobiology, SurgVision, Synaffix


Acerta Pharma (Acquired by ), Lanthio Pharma (Acquired by MorphoSys), arGEN-X (IPO)